ClinVar Miner

Submissions for variant NM_000784.4(CYP27A1):c.536A>G (p.Asn179Ser)

gnomAD frequency: 0.00006  dbSNP: rs145080072
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 4
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Eurofins Ntd Llc (ga) RCV000373213 SCV000341881 uncertain significance not provided 2016-05-03 criteria provided, single submitter clinical testing
Illumina Laboratory Services, Illumina RCV000397675 SCV000427465 uncertain significance Cholestanol storage disease 2018-01-12 criteria provided, single submitter clinical testing This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score, this variant could not be ruled out of causing disease and therefore its association with disease required further investigation. A literature search was performed for the gene, cDNA change, and amino acid change (if applicable). No publications were found based on this search. This variant was therefore classified as a variant of unknown significance for this disease.
Invitae RCV000397675 SCV001691151 likely benign Cholestanol storage disease 2024-01-29 criteria provided, single submitter clinical testing
Ambry Genetics RCV002348013 SCV002645125 uncertain significance Cardiovascular phenotype 2022-01-17 criteria provided, single submitter clinical testing The p.N179S variant (also known as c.536A>G), located in coding exon 3 of the CYP27A1 gene, results from an A to G substitution at nucleotide position 536. The asparagine at codon 179 is replaced by serine, an amino acid with highly similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.